{'fraction_non_alphanumeric': 0.053864168618266976, 'fraction_numerical': 0.03278688524590164, 'mean_word_length': 4.896551724137931, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety of ciprofloxacin. A review.

In clinical trials phase II and III world wide 8,861 courses of ciprofloxacin were entered into the data base for safety evaluation. The following adverse reactions were observed-gastrointestinal 5%, metabolic and nutritional 4.6%, central nervous system 1.6%, skin 1.4%, hemic and lymphatic 1%, cardiovascular 0.4%, body as a whole 0.4%, urogenital 0.3%, special senses 0.3%, musculo-skeletal 0.1%, respiratory 0.08%. Total incidence of adverse reactions was 10.2%. Ciprofloxacin interacts with theophylline and certain antacids. Caution should be exercised in treating patients with known history of convulsions. Crystalluria does not appear to be a problem. Ciprofloxacin is well tolerated and side effects are usually mild or moderate in intensity. However, unusual and unexpected reactions have to be watched for.